eli lilly and company corporate center indianapolis indiana 46285 usa www com date october 20 2005 final for release immediately refer to 317 276 2506 phil belt reports 73 eps 10 percent sales growth in the third quarter newer products contribute more than 650 million or 18 of total q3 nyse lly today announced financial results highlights increased 3 601 billion alimta cialis non joint venture cymbalta forteo strattera symbyax xigris yentreve contributed 651 6 accounted compared with 12 2004 which was launched us late august treatment major depressive disorder september diabetic peripheral neuropathic pain has achieved 544 8 since its launch as detailed icos earnings generated positive this 19 net income per share 5
